Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Single-arm, Exploratory Study of SBRT Sequential CapeOX Chemotherapy Combined With Bevacizumab and Sintilimab in First-line Treatment of Metastatic Colorectal Cancer

NCT05438108 is registered in ClinicalTrials.gov with Huazhong University of Science and Technology as lead sponsor.

NCT NCT05438108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05438108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Single-arm, Exploratory Study of SBRT Sequential CapeOX Chemotherapy Combined With Bevacizumab and Sintilimab in First-line Treatment of Metastatic Colorectal Cancer
Lead sponsor
Huazhong University of Science and Technology
Phase
Phase 2
Overall status
Unknown status
Start date
July 1, 2022
Completion date
January 31, 2024
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer